Overview

Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

This study is designed to demonstrate that formoterol 12µg and 24µg delivered by a new inhalation device (Concept1) are equivalent to the corresponding dose of formoterol delivered by the Aerolizer device in terms of efficacy, in patients with persistent asthma.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Formoterol Fumarate